FDA Issues Public Warning Re Elidel and Protopic

On February 15, 2005 the US Food and Drug Administration (FDA) Pediatric Advisory Committee recommended a "black box" warning be placed on topical calcineurin inhibitor (Elidel® - pimecrolimus and Protopic® - tacrolimus), followed by the FDA issuing a Public Health Advisory on March 10, 2005 regarding the safety concerns.

Click on one of the titles below to read statements regarding the FDA's black box warning:

American Academy of Dermatology (AAD)
www.aad.org/public/News/NewsReleases/fda_decision.htm

Canadian Dermatology Association (CDA)
www.dermatology.ca/english/public-patients/positions_e.html

National Eczema Association for Science and Education (NEASE)
www.nationaleczema.org/NEASEStatementToPatients.Mar2005%20FINAL.doc

Inflammatory Skin Disease Institute
www.isdionline.org/current.htm